zavegepant Archives - Medical Design Sourcing

[Zavegepant image from PubChem]

The Lancet has published Phase 3 study results for zavegepant, an investigational nasal spray for the acute treatment of migraine. The study found that a single 10 mg intranasal dose of zavegepant was more effective than placebo for pain relief and freedom from the most bothersome symptom at two hours post-dose.

Zavegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a protein involved in transmitting pain signals in the brain.

Zavegepant’s nasal formulation could be particularly valuable for migraine patients who experience nausea and difficulty swallowing.

Zavegepant is now a Pfizer asset

Pfizer (NYSE:PFE) acquired the asset through last year’s purchase of Biohaven Pharmaceutical Holding Company (NYSE:BHVN), which had commercialized the dual-acting migraine therapy Nurtec ODT (rimegepant).

In the recent …

Pfizer (NYSE:PFE) today announced that it has entered into an agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), which is best known for Nurtec ODT (rimegepant), a dual-acting migraine therapy.

Pfizer will pay $148.50 per share in cash to acquire Biohaven, totaling approximately $11.6 billion.

Nurtec generated $462 million in revenue in 2021. Pfizer anticipates that the acquisition will fuel continued growth through the remainder of the decade and beyond.

Evaluate Pharma projects that Nurtec could generate $2 billion in international sales by 2026.

Nurtec image courtesy of Biohaven

Nurtec is a calcitonin gene-related peptide (CGRP) agonist that has emerged as a popular preventive treatment for migraines with or without aura.

Notable competitors in the class include Qulipta (atogepant) from AbbVie (NYSE:ABBV and Ubrelvy (ubrogepant) from AbbVie subsidiar…